For a deeper look at what GLP-1 approval actually required, Meto's clinical overview of GLP-1 drugs provides useful context as does our recent piece on Foundayo (orforglipron), the first oral GLP-1 to reach approval
Other side effects include diarrhoea (up to 30% on semaglutide and 20% on tirzepatide), vomiting (25% vs 12% respectively), constant sinusistis/pharyngitis (up to 20%), headaches (15% vs 6%), abdominal pain (10% vs 5%)
Some people are needle anxious, some dislike the medical feeling of injecting and others simply prefer the discretion of taking a tablet. Who can use it
Two common approaches to tapering are often used
Effects of testosterone treatment in older men
FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor